Mar 20, 2024, 08:31 AM by

Lindus Health Introduces Comprehensive “All-In-One CRO” Package for CNS, Neurology, and Psychiatric Clinical Trials

Mar 20, 2024, 08:31 AM by

DNAnexus is integrating new NVIDIA NIM and CUDA-X microservices to its Precision Health Data Cloud.

Mar 20, 2024, 08:31 AM by

Cambridge Healthtech Institute announces the final agenda for the inaugural Bio-IT World: Venture, Innovation & Partnering Conference—a gathering of leading investors, executives, research institutions, biotech and informatics innovators, startups, and strategics whose creative partnerships are catalyzing today’s drug discoveries. The April 17 Boston event, drawing heavily from leaders within the renowned Boston/Cambridge, Mass. biotech community, will be part of the 23rd annual Bio-IT World Conference & Expo April 15-17, which will attract more than 3,000 life science and IT innovators.

Mar 20, 2024, 08:31 AM by

The initiation of the phase I clinical trial for ABBV-1882 marks a significant milestone in the quest for novel HIV treatments. With its unique mechanism of action and potential to transform HIV management, ABBV-1882 represents a beacon of hope for individuals living with HIV and underscores AbbVie's unwavering commitment to advancing science for the benefit of patients worldwide.

Mar 20, 2024, 08:31 AM by

Biopharma PEG Scientific Inc. will showcase its latest high-purity polyethylene glycol (PEG) derivatives and custom synthesis solutions at Booth No. 718 in PEGS Boston Summit 2024 and at TIDES USA 2024 at Booth No. 935.

Mar 20, 2024, 08:31 AM by

Hunan Huateng Pharmaceutical Co., Ltd is set to present its groundbreaking solutions at CPHI Japan 2024, showcasing expertise in PEG derivatives and CDMO services. Attendees are encouraged to visit Booth No. 4X-08 to explore cutting-edge offerings and engage with industry experts.

Mar 20, 2024, 08:31 AM by

Mar 20, 2024, 08:31 AM by

Mar 19, 2024, 08:35 AM by

New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day

Mar 19, 2024, 08:35 AM by

Life Sciences Industry Veteran to Lead Development and Execution of Growth and Innovation Strategy, Expanding Global Reach of Bioforum’s Biometric Services and Solutions

Mar 19, 2024, 08:35 AM by

Mar 19, 2024, 05:00 AM by User Not Found

Bio-IT World | Bio-IT World today announced the 2024 Innovative Practices Awards winners. Six projects were honored. Companies driving the winning entries included AstraZeneca, DNAnexus, Pistoia Alliance, Regeneron, Tempus, and UK Biobank.

Mar 18, 2024, 08:36 AM by

Mar 15, 2024, 08:10 AM by

Now, for the first time, a new paper in Nature Biotechnology from clinical stage AI-driven biotechnology company Insilico Medicine reveals the entire process behind the company’s lead AI-designed molecule for an AI-discovered target for the chronic, progressive and often fatal rare lung disease idiopathic pulmonary fibrosis (IPF), which impacts 5 million people worldwide.

Mar 15, 2024, 08:09 AM by

Specialist Biometrics CRO, Veramed has announced the appointment of Karen Curran as Chief Strategy Officer.

Mar 14, 2024, 08:47 AM by

New AvalonSelect Genetic Network Offers Health Plans Control, Quality, and Savings in Genetic Testing

Mar 14, 2024, 05:00 AM by User Not Found

Bio-IT World | Cancer Grand Challenges—a global funding initiative co-founded by the National Cancer Institute and Cancer Research UK—has announced five new global teams selected to each receive up to $25M over five years to take on four of cancer’s toughest challenges.

Mar 13, 2024, 08:16 AM by

Mar 13, 2024, 08:16 AM by

Darling Ingredients’ health brand Rousselot, a global leader in gelatin- and collagen-based solutions, announced today that its high-quality, research- and technical-grade gelatins are now available for online purchase in Canada, Europe, South Korea and the U.S. through BIO INX, a pioneering developer and distributor of materials for 3D bioprinting.

Mar 13, 2024, 05:00 AM by User Not Found

Bio-IT World | When it comes to research on amyotrophic lateral sclerosis (ALS), every stakeholder—most especially patients—knows time is of the essence. From diagnosis to death, life expectancy from the debilitating neuromuscular disease can be two years or less.